{"id":62237,"date":"2026-06-04T14:24:10","date_gmt":"2026-06-04T14:24:10","guid":{"rendered":"https:\/\/www.europesays.com\/ai\/62237\/"},"modified":"2026-06-04T14:24:10","modified_gmt":"2026-06-04T14:24:10","slug":"openai-anthropic-microsoft-ceos-call-for-stricter-laws-against-ai-biothreats","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ai\/62237\/","title":{"rendered":"OpenAI, Anthropic & Microsoft CEOs Call for Stricter Laws Against AI Biothreats"},"content":{"rendered":"


\n
\n
\n <\/p>\n

While AI is supercharging biotech advancements, it could potentially help bad actors create the next healthcare crisis.<\/p>\n


\n <\/p>\n

MITSloan ME Editorial<\/a>
\n
\n less than a minute ago <\/p>\n

<\/p>\n


\n
\n
\n
\n
\n
\n
\n Subscribe
\n<\/a>
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\n
\nShare<\/a><\/p>\n


\n Share
\n OpenAI, Anthropic & Microsoft CEOs Call for Stricter Laws Against AI Biothreats
\n
\n
\n
\n
\n Twitter<\/a>
\n
\n
\n
\n Facebook<\/a>
\n
\n
\n
\n
\n
\n
\n Whatsapp<\/a>
\n
\n
\n
\n
\n
\n
\n
\n
\n Linkedin<\/a><\/p>\n

<\/p>\n


\n \"\"\/
\n
\n
\n <\/p>\n

Artificial intelligence has greatly eased public access to information. However, this change has raised concerns among AI leaders and experts. In a public letter to the US Congress, OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei, Microsoft AI CEO Mustafa Suleyman, and over 50 signatories urged safeguards in the handling of synthetic DNA and RNA, essential components for developing vaccines and other biotech innovations.\u00a0\u00a0<\/p>\n

\u200bThe signatories also include scientists, national security experts, and executives from gene synthesis companies.<\/p>\n

\u201cAI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode,\u201d the letter said<\/a>.<\/p>\n

Experts noted that while the ability to order synthetic DNA online had accelerated vaccine development, there exists a blind spot where a bad actor could theoretically order DNA sequences to reconstruct dangerous viruses.<\/p>\n

While synthesis companies have had voluntary screening since 2009, it isn\u2019t universal.<\/p>\n

\u201cWe call on legislators to make screening of orders for synthetic nucleic acids \u2014 and the equipment needed to make them \u2014 mandatory,\u201d it added.<\/p>\n

The letter comes shortly after US President Donald Trump signed an executive order creating a voluntary framework that will require AI developers to share advanced models with the government before public release.<\/p>\n

AI for Biological R&D<\/p>\n

Global AI in biotechnology was valued at $3.51B in 2024, $4.16B in 2025, and is expected to touch $22.72B by 2035, according to Markets and Markets.<\/p>\n

In a milestone, Demis Hassabis of Google\u2019s DeepMind AI lab was jointly awarded the 2024 Nobel Prize in Chemistry for groundbreaking work leveraging AI to predict protein structures and accelerate drug discovery.<\/p>\n

\u201cI feel like (AI tools) allow individual scientists to do so much more. Because these systems are tools. They\u2019re very good at analyzing data and identifying patterns and structure. But they can\u2019t figure out what the right question, hypothesis, or conjecture is. All of that\u2019s got to come from the human scientist. I think the best scientists paired with these kinds of tools will be able to do incredible things, perhaps even in smaller teams than they used to be able to, because they can rely on the tools to do a lot of the legwork,\u201d he said<\/a> in December 2024.<\/p>\n

In May, OpenAI announced<\/a> Rosalind Biodefense, a new initiative aimed at encouraging the development of high-impact defensive applications of AI in the life sciences through its GPT\u2011Rosalind, a frontier reasoning model built for life sciences research.<\/p>\n